Market Whales and Their Recent Bets on AMGN Options
Market Whales and Their Recent Bets on AMGN Options
Deep-pocketed investors have adopted a bullish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMGN usually suggests something big is about to happen.
有实力的投资者对Amgen (纳斯达克：AMGN) 采取了看涨的策略，这是市场玩家不应忽视的。我们在Benzinga跟踪公开期权记录的过程中发现了这一重大举措。这些投资者的身份尚不清楚，但AMGN的如此大规模举动通常意味着即将发生一些大事。
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Amgen. This level of activity is out of the ordinary.
我们从今天的观察中获得了这些信息，当Benzinga的期权扫描器突出显示Amgen的12次非凡期权交易时。这种活动水平不同寻常。
The general mood among these heavyweight investors is divided, with 58% leaning bullish and 33% bearish. Among these notable options, 3 are puts, totaling $131,892, and 9 are calls, amounting to $509,076.
这些大户投资者中总体情绪分化，有58%倾向于看涨，33%倾向于看淡。在这些值得注意的期权当中，有3单看跌期权，总金额为$131,892，还有9单看涨期权，总金额为$509,076。
What's The Price Target?
目标价是多少？
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $270.0 and $400.0 for Amgen, spanning the last three months.
在评估成交量和未平仓合约后，很明显，主要市场巨头正在关注AMGN的价格区间，该区间跨足过去三个月，价格区间为$270.0至$400.0。
Volume & Open Interest Development
成交量和持仓量的评估是期权交易中的一个关键步骤。这些指标揭示了阿里巴巴集团（Alibaba Gr Hldgs）特定执行价格期权的流动性和投资者兴趣。下面的数据可视化了在过去30天内，阿里巴巴集团（Alibaba Gr Hldgs）在执行价格在74.0美元到120.0美元区间内的看涨看跌期权中，成交量和持仓量的波动情况。
In terms of liquidity and interest, the mean open interest for Amgen options trades today is 710.62 with a total volume of 2,420.00.
就流动性和兴趣而言，今天Amgen期权交易的平均未平仓合约为710.62，总量为2,420.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for Amgen's big money trades within a strike price range of $270.0 to $400.0 over the last 30 days.
在下面的图表中，我们能够跟踪Amgen大宗交易的看涨和看跌期权的成交量和未平仓合约的发展趋势，在$270.0至$400.0的执行价区间内跨足了过去30天。
Amgen 30-Day Option Volume & Interest Snapshot
安进30天期权成交量和持仓量快照
Noteworthy Options Activity:
值得注意的期权活动：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | SWEEP | BULLISH | 01/16/26 | $37.0 | $35.35 | $37.0 | $370.00 | $136.9K | 63 | 37 |
| AMGN | CALL | TRADE | BULLISH | 01/17/25 | $85.0 | $81.5 | $83.81 | $270.00 | $83.8K | 706 | 10 |
| AMGN | PUT | SWEEP | BEARISH | 10/18/24 | $9.1 | $7.9 | $9.15 | $325.00 | $64.7K | 556 | 71 |
| AMGN | CALL | SWEEP | BEARISH | 08/02/24 | $6.25 | $6.0 | $6.0 | $345.00 | $63.6K | 556 | 338 |
| AMGN | CALL | TRADE | BEARISH | 12/20/24 | $11.9 | $9.85 | $10.0 | $400.00 | $50.0K | 66 | 0 |
| 标的 | 看跌/看涨 | 交易类型 | 情绪 | 到期日 | 卖盘 | 买盘 | 价格 | 执行价格 | 总交易价格 | 未平仓合约数量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看涨 | SWEEP | 看好 | 01/16/26 | $37.0 | $35.35 | $37.0 | $370.00 | $136.9千美元 | 63 | 37 |
| AMGN | 看涨 | 交易 | 看好 | 01/17/25 | $85.0 | $81.5 | $83.81 | $270.00 | $83.8千美元 | 706 | 10 |
| AMGN | 看跌 | SWEEP | 看淡 | 10/18/24 | $9.1 | $7.9 | 9.15美元 | $325.00 | $64.7K | 556 | 71 |
| AMGN | 看涨 | SWEEP | 看淡 | 08/02/24 | 6.25美元 | $6.0 | $6.0 | $345.00 | $63.6K | 556 | 338 |
| AMGN | 看涨 | 交易 | 看淡 | 12/20/24 | $11.9 | $9.85 | $10.0 | $400.00 | $50.0K | 66 | 0 |
About Amgen
关于安进
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安进是生物技术制药领域的领导者。旗舰药物包括增加红细胞计数的艾普毕与阿拉尼许、增强免疫系统的奈帕姆和奈乌细胞移植因子、以及针对炎症性疾病的恩布瑞尔和欧特兹拉。安进在2006年推出了首个癌症治疗药物Vectibix，并推出了增强骨密度的药物Prolia/Xgeva（于2010年获批）和Evenity（于2019年获批）。对Onyx的收购增强了该公司在治疗肿瘤领域的药物组合，其中包括Kyprolis。最近推出的药物包括Repatha（降低胆固醇）、Aimovig（缓解偏头痛）、Lumakras（治疗肺癌）以及Tezspire（治疗哮喘）。2023年Horizon收购带来了几种罕见疾病药物，其中包括治疗甲状腺眼病的Tepezza。安进还拥有不断增长的生物类似物组合。
After a thorough review of the options trading surrounding Amgen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
在对Amgen周边的期权交易进行全面审查之后，我们开始更仔细地审视该公司。这包括对其当前市场状况和表现的评估。
Amgen's Current Market Status
Amgen的当前市场状况
- With a volume of 618,337, the price of AMGN is up 0.12% at $336.0.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 12 days.
- 在成交量为618,337的情况下，AMGN的价格为336.0美元，上涨了0.12%。
- RSI因子暗示底层股票可能被超买。
- 下一次公布的收益预计将在12天后发行。
Expert Opinions on Amgen
安进的专家意见
In the last month, 2 experts released ratings on this stock with an average target price of $321.5.
在过去一个月中，有2位专家对这只股票进行了评级，平均目标价为321.5美元。
- Consistent in their evaluation, an analyst from Argus Research keeps a Buy rating on Amgen with a target price of $340.
- Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Amgen with a target price of $303.
- 在他们的评估中保持一致的是，Argus Research的一位分析师对Amgen保持买入评级，目标价为340美元。
- 在他们的评估中保持一致的是，摩根士丹利的一名分析师对Amgen保持平权评级，目标价为303美元。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Amgen options trades with real-time alerts from Benzinga Pro.
期权交易具有更高的风险和潜在回报。精明的交易者通过不断学习、调整策略、监控多个因子和密切关注市场走势来管理这些风险。通过Benzinga Pro的实时提醒了解最新的安进期权交易。